<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127234">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446003</url>
  </required_header>
  <id_info>
    <org_study_id>8457-004</org_study_id>
    <nct_id>NCT01446003</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)</brief_title>
  <official_title>A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of treatment with multiple doses of MK-8457 on systolic
      blood pressure in participants with mild to moderate hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 10 in 24-hour mean ambulatory systolic blood pressure</measure>
    <time_frame>Baseline and Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 10 in 24-hour mean ambulatory diastolic blood pressure</measure>
    <time_frame>Baseline and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 10 in Maximum Moving Average (maxMAΔ) Blood Pressure Measured over 4 hours</measure>
    <time_frame>Up to 4 hours postdose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from 0 to 12 hours (AUC0-12hr)</measure>
    <time_frame>Predose and up to 12 hours postdose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of MK-8457 in the plasma</measure>
    <time_frame>Predose and up to 12 hours postdose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Predose and up to 12 hours postdose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) of MK-8457</measure>
    <time_frame>Predose and up to 12 hours postdose on Days 1 and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>MK-8457-Placebo Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment will be separated by a 10-day washout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-MK-8457 Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment will be separated by a 10-day washout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8457</intervention_name>
    <description>10 x 10-mg capsule twice daily (BID) for 10 days</description>
    <arm_group_label>MK-8457-Placebo Sequence</arm_group_label>
    <arm_group_label>Placebo-MK-8457 Sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MK-8457</intervention_name>
    <description>10 x 10-mg capsule BID for 10 days</description>
    <arm_group_label>MK-8457-Placebo Sequence</arm_group_label>
    <arm_group_label>Placebo-MK-8457 Sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, must be of non-childbearing potential

          -  If male with female partner(s) of child-bearing potential must agree to use a
             medically acceptable method of contraception during the study and for 90 days after
             the last dose of study drug

          -  Body mass index (BMI) ≤35 kg/m^2

          -  Mild-to-moderate hypertension requiring treatment with one or more antihypertensive
             agents

          -  Receiving stable treatment for hypertension for at least 8 weeks prior to the start
             of dosing and continuing therapy for duration of study

          -  No clinically significant arrhythmias or clinically significant abnormality on
             electrocardiogram

          -  Nonsmoker and/or has not used nicotine or nicotine-containing products for at least
             approximately 6 months

        Exclusion Criteria:

          -  Any illness that might confound the results of the study or poses an additional risk

          -  History of stroke, chronic seizures, or major neurological disorder

          -  Clinically significant endocrine, gastrointestinal, hematological, hepatic,
             immunological, renal, respiratory, or genitourinary abnormalities or diseases

          -  Clinically significant cardiovascular disease or has active angina

          -  History of malignant neoplastic disease

          -  Taking 325 mg aspirin daily

          -  Taking 3 or more medications for the treatment of hypertension

          -  Unable to refrain from or anticipates the use of any non-steroidal anti-inflammatory
             drugs (NSAIDs)

          -  Consumes excessive amounts of alcohol and/or coffee, tea, cola, or other caffeinated
             beverages

          -  Has had major surgery, donated or lost 1 unit of blood or participated in another
             investigational study within 4 weeks

          -  Significant multiple and/or severe allergies

          -  Regular user of any illicit drugs or has a history of drug (including alcohol) abuse
             within approximately 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Call for Information</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 20, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
